Please try another search
For the three months ended 31 March 2018, Juniper Pharmaceuticals Inc revenues increased 38% to $15.5M. Net income applicable to common stockholders totaled $772K vs. loss of $1.4M. Revenues reflect Product segment increase of 30% to $10.1M, Services segment increase of 55% to $5.5M, Switzerland segment increase of 32% to $10.3M, United States segment increase from $1.6M to $3.5M.
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Total Revenue | 15.52 | 11.79 | 12.99 | 13.96 |
Gross Profit | 6.5 | 4.75 | 5.27 | 6.31 |
Operating Income | 1.02 | -0.52 | -1.53 | -0.36 |
Net Income | 0.77 | 1.17 | -1.41 | -0.38 |
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Total Assets | 64.54 | 61.22 | 61.76 | 60.03 |
Total Liabilities | 13.52 | 19.71 | 21.84 | 19.73 |
Total Equity | 51.02 | 41.51 | 39.91 | 40.3 |
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -1.1 | 2.13 | 2.23 | 0.49 |
Cash From Investing Activities | -0.88 | -2.84 | -2.4 | -1.4 |
Cash From Financing Activities | 1.19 | 1.04 | 1.17 | 1.3 |
Net Change in Cash | -0.76 | 0.45 | 1.11 | 0.47 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review